Johnson & Johnson $JNJ Stock: TrinityBridge Ltd Boosts Position

TrinityBridge Ltd raised its stake in Johnson & Johnson (NYSE:JNJ) by 55.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 245,209 shares of the company’s stock after acquiring an additional 87,682 shares during the quarter. Johnson & Johnson makes up 1.9% of TrinityBridge Ltd’s holdings, making the stock its 17th biggest position. TrinityBridge Ltd’s holdings in Johnson & Johnson were worth $64,960,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Lyell Wealth Management LP raised its holdings in Johnson & Johnson by 3.4% during the 3rd quarter. Lyell Wealth Management LP now owns 8,793 shares of the company’s stock valued at $2,328,000 after acquiring an additional 293 shares during the period. Associated Banc Corp bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at $39,302,000. Putney Financial Group LLC purchased a new stake in Johnson & Johnson during the 3rd quarter worth about $182,000. Watershed Private Wealth LLC boosted its stake in Johnson & Johnson by 85.8% in the 3rd quarter. Watershed Private Wealth LLC now owns 1,945 shares of the company’s stock worth $515,000 after purchasing an additional 898 shares during the period. Finally, Richwood Investment Advisors LLC lifted its holdings in shares of Johnson & Johnson by 3.5% in the third quarter. Richwood Investment Advisors LLC now owns 5,207 shares of the company’s stock worth $1,379,000 after buying an additional 178 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer Taubert sold 15,000 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.16% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Wall Street analysts remain moderately bullish on J&J’s prospects, according to a review of analyst views. Read article
• Neutral Sentiment: State Street’s Health Care SPDR added J&J shares as part of a $175.3 million purchase that increased all 60 of the fund’s holdings. This indicates fund buying, but the report does not specify J&J’s allocation or suggest a company-specific investment view. Read article
• Neutral Sentiment: Smith+Nephew cut its outlook and confirmed failed merger discussions with J&J’s orthopedics unit. The talks’ failure removes a potential transaction, but the report does not detail any direct financial impact on J&J. Read article
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors. The announcement could create negative legal overhang, although it does not provide details about the claims or establish wrongdoing. Read article

Analyst Ratings Changes

JNJ has been the topic of several research analyst reports. Sanford C. Bernstein set a $270.00 price target on shares of Johnson & Johnson in a report on Thursday, October 15th. Bank of America reissued a “neutral” rating and set a $278.00 price objective on shares of Johnson & Johnson in a report on Tuesday, September 29th. UBS Group set a $270.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 14th. Erste Group Bank cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Finally, Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $275.92.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $276.62 on Thursday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The firm has a market cap of $665.92 billion, a P/E ratio of 41.91, a P/E/G ratio of 2.63 and a beta of 0.22. The business’s 50 day moving average price is $265.67 and its 200-day moving average price is $247.74. Johnson & Johnson has a fifty-two week low of $185.12 and a fifty-two week high of $282.02.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson’s payout ratio is currently 81.21%.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.